Research papers

 [2025]

*1. Komatsu M, Komatsu R, Sakai A, Yasutomi S, Harada N, Aoyama R, Teraya N, Takeda K, Natsume T, Taniguchi T, Iwamoto K, Matsuoka R, Sekizawa A, Hamamoto R. Establishment of High-Precision Ultrasound Diagnosis Methods Based on the Introduction of Deep Learning. IEEE Rev Biomed Eng. 2025 Dec 31;PP. doi: 10.1109/RBME.2025.3645229. Online ahead of print. [pubmed]

*2. Toyohara Y, Sone K, Kumegawa K, Yamamoto Y, Hachijo R, Tanimoto S, Inoue F, Kukita A, Taguchi A, Ikemura M, Miyamoto Y, Tanikawa M, Iriyama T, Mori-Uchino M, Hamamoto R, Ushiku T, Oda K, Hirota Y, Maruyama R, Osuga Y. Synthetic lethality from the combination of a histone methyltransferase, SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma. BMC Cancer. 2025 Dec 16;25(1):1873. [pubmed]

*3. Yazaki S, Kitadai R, Momozawa Y, Yoshida T, Yamanaka T, Shiino S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Hamamoto R, Shimizu C, Shimomura A, Shimoi T, Sudo K, Yoshida M, Sunami K, Shiraishi Y, Kuchiba A, Hori M, Katanoda K, Takata S, Ogawa A, Torasawa M, Mochizuki A, Shimada Y, Fujii E, Hirata M, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Matsuda K, Tokunaga K, Kawai Y, NCBN Controls WGS Consortium, Biobank Japan Project, Omata M, Ohtake T, Suto A, Onishi T, Naito Y, Yamashita T, Yonemori K, Kohno T, Shiraishi K. Germline variants of the POLH and RAD51 genes confer susceptibility to hormone receptor-negative young-onset breast cancer. NPJ Breast Cancer. 2025 Nov 28;11(1):133. [pubmed]

*4. Suda K, Yoshida Y, Sato H, Ohara S, Hamada A, Yotsukura M, Shiraishi K, Hamamoto R, Chiba Y, Kohno T, Yatabe Y, Watanabe SI, Tsutani Y, Mitsudomi T. Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Non-Squamous NSCLC with Pure Solid Tumor Appearance. Cancer Res Commun. 2025 Dec 1;5(12):2186-2196. [pubmed]

*5. Miyakoshi J, Shiraishi K, Mochizuki A, Tateishi A, Shimoda-Igawa Y, Torasawa M, Ono H, Ohno M, Yoshida Y, Yoshida T, Kaneko S, Yagishita S, Hamada A, Yatabe Y, Goto Y, Suzuki T, Narita Y, Watanabe S, Hamamoto R, Kohno T. Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer. J Thorac Oncol. 2025 Nov 7:S1556-0864(25)02894-1. [pubmed]

*6. Nukaga S, Shiraishi K, Hamabe K, Mochizuki A, Hamaguchi Y, Ogawa E, Le NT, Shimada Y, Ono H, Nishinakamura H, Kobayashi Y, Hamamoto J, Ui A, Araki M, Sagae Y, Ohgino K, Sugihara K, Endo S, Miyakoshi J, Shiraishi Y, Yasuda H, Okuno Y, Yoshida T, Goto Y, Ohe Y, Watanabe SI, Yatabe Y, Nishikawa H, Hamamoto R, Kohno T, Nakaoku T. Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities. Nat Commun. 2025 Nov 6;16(1):9754. [pubmed]

*7. Takeuchi T, Horinouchi H, Takasawa K, Mukai M, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Yamamoto N, Ohe Y, Miyake M, Watanabe H, Kusumoto M, Aoki T, Nishimura K, Hamamoto R. A series of natural language processing for predicting tumor response evaluation and survival curve from electronic health records. BMC Med Inform Decis Mak. 2025 Feb 17;25(1):85. [pubmed]

*8. Ishizu K, Takahashi S, Kouno N, Takasawa K, Takeda K, Matsui K, Nishino M, Hayashi T, Yamagata Y, Matsui S, Yoshikawa T, Hamamoto R. Establishment of a machine learning model for predicting splenic hilar lymph node metastasis. NPJ Digit Med. 2025 Feb 11;8(1):93. [pubmed]

*9. Kitadai R, Yazaki S, Kuchiba A, Yamanaka T, Shiino S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Yoshida T, Hamamoto R, Shimizu C, Shimomura A, Kojima Y, Shimoi T, Momozawa Y, Sudo K, Yoshida M, Sunami K, Hori M, Katanoda K, Shimada Y, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Omata M, Ohtake T, Suto A, Onishi T, Naito Y, Yamashita T, Yonemori K, Kohno T, Shiraishi K. Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer. Cancer Sci. Apr;116(4):1048-1058. doi: 10.1111/cas.70002. 2025. [pubmed]

*10. Komatsu M, Teraya N, Natsume T, Harada N, Takeda K, Hamamoto R. Clinical Application of Artificial Intelligence in Ultrasound Imaging for Oncology. JMA J. 2025 Jan 15;8(1):18-25. doi: 10.31662/jmaj.2024-0203. [pubmed]

*11. Fujii E, Kato MK, Ono H, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H. TP53 Mutations and PD-L1 Amplification in Vulvar Adenocarcinoma of the Intestinal Type: Insights From Whole Exome Sequencing of 2 Cases. Int J Gynecol Pathol. 2025 Jan 9. doi: 10.1097/PGP.0000000000001093. Int J Gynecol Pathol. 2025 Jul 1;44(4):358-363. [pubmed]

*12. Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y. Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma. Lung Cancer. 2025 Mar 11;202: 108494. [pubmed]

*13. Shinkai N, Asada K, Machino H, Takasawa K, Takahashi S, Kouno N, Komatsu M, Hamamoto R, Kaneko S. SEgene identifies links between super enhancers and gene expression across cell types. NPJ Syst Biol Appl. 2025 May 19;11(1):49. [pubmed]

*14. Yazaki S, Hori M, Aiba H, Momozawa Y, Yoshida M, Shiino S, Harano K, Yamauchi C, Yamanaka T, Miwa M, Matsuda K, Kawai Y, Kobayashi-Kato M, Kitagawa M, Saito M, Nakagomi H, Tachibana K, Sakamoto I, Takahashi K, Asami Y, Katanoda K, Kuchiba A, Yoshida H, Ishikawa M, Shimoi T, Sudo K, Shimizu C, Shimomura A, Murata T, Yamashita Y, Kogawa T, Fujiwara S, Saji H, Kato H, Miyagi E, Iwasaki Y, Aoi T, Takata S, Ogasawara A, Ohtake T, Fujimori K, Hirotsu Y, Nagashima M, Komatsu M, Hamamoto R, Hirata M, Yoshida T, Honda T, Hiranuma K, Matsuda M, Shimada Y, Sunami K, Noiri E, Omae Y, Matsumoto K, Okamoto A, Omata M, Watanabe T, Miyagi Y, Murakami Y, Tokunaga K, Hasegawa K, Kato T, Onishi T, Yamashita T, Naito Y, Suto A, Yonemori K, Kohno T, Shiraisihi K; BioBank Japan Project; NCBN Controls WGS Consortium. Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis. EBioMedicine. 2025 May 21;116: 105758. [pubmed]

*15. Hamamoto R. Editorial for Innovative Artificial Intelligence System in the Children's Hospital in Japan. JMA J. 2025 Apr 28;8(2):361-362. [pubmed]

*16. Cho H, Shiraishi K, Sunami K, Momozawa Y, Yoshida T, Matsumoto S, Matsuda K, Saito M, Goto A, Honda T, Mochizuki A, Torasawa M, Daigo Y, Shimizu K, Kunitoh H, Yoshida Y, Hirata M, Shimada Y, Ueki M, Ono H, Gotoh M, Igawa YS, Tateishi A, Yamaguchi Y, Higashiyama RI, Machida E, Iwasaki M, Kawai Y, Yasuda H, Hamamoto J, Imoto I, Matsushita H, Takata S, Aoi T, Kaneko S, Kuchiba A, Shimomura A, Fukami M, Hattori K, Ozaki K, Asano Y; NCBN Controls WGS Consortium; Project BJ, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Yamaura T, Yoshida T, Goto Y, Horinouchi H, Miyazaki Y, Ito H, Nagashima T, Ohtaki Y, Imai K, Minamiya Y, Okubo K, Inazawa J, Shiraishi Y, Tokunaga K, Kamatani Y, Yatabe Y, Goto K, Tsuboi M, Watanabe SI, Ohe Y, Murakami Y, Matsuo K, Hamamoto R, Kohno T. Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma. J Thorac Oncol. 2025 Jun 12:S1556-0864(25)00764-6. [pubmed]

*17. Higuchi D, Yamaguchi M, Fujii E, Kato MK, Hiranuma K, Asami Y, Ono H, Koyama T, Komatsu M, Hamamoto R, Terao Y, Matsumoto K, Sekizawa A, Ishikawa M, Kohno T, Yoshida H, Makinoshima H, Shiraishi K, Kato T. TP53 gene and pathway alterations in gastric-type adenocarcinoma of the cervix. JNCI Cancer Spectr. 2025 Sep 1;9(5):pkaf082. [pubmed]

*18. Uozumi T, Sugimoto M, Mizuguchi Y, Toyoshima N, Abe S, Hamamoto R, Saito Y. Intraoperative mixed reality support for endoscopic submucosal dissection of a large laterally spreading tumor in the rectum. Endoscopy. 2025 Dec;57(S 01):E923-E924. [pubmed]

*19. Tateishi A, Horinouchi H, Kouno N, Takeda K, Takasawa K, Mizuno T, Okubo Y, Yoshida Y, Miyake M, Kusumoto M, Inaba K, Igaki H, Yatabe Y, Mukai M, Mihara N, Nishino J, Kuchiba A, Shibata T, Shiraishi K, Watanabe SI, Komatsu M, Kohno T, Ohe Y, Hamamoto R. Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data. Lung Cancer. 2025 Sep;27:108727. [pubmed]

*20. Kato MK, Kawai T, Okada H, Kondo T, Shiraishi T, Yamaguchi M, Higuchi D, Komatsu M, Hamamoto R, Matumoto K, Terao Y, Kato T, Kohno T, Ishikawa M, Shiraishi K, Yoshida H. Comparison between a Luminex-based multiplex kit with a sequence-specific oligonucleotide probe and next-generation sequencing for the detection of POLE oncogenic mutations in endometrial cancer. Virchows Arch. 2025 Aug 4. doi: 10.1007/s00428-025-04204-4. Online ahead of print. [pubmed]

*21. Blechter B, Wang X, Dai J, Karsonaki C, Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Hung RJ, Chen K, Shu XO, Kim YT, Choudhury PP, Williams J, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Li S, Zhang T, Breeze C, Wang Z, Bassig BA, Kim JH, Albanes D, Wong Sm JY, Shin MH, Chung LP, Yang Y, Zheng H, Dai H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Ho JCM, Daigo Y, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood HD, Kunitoh H, Watanabe SI, Miyagi Y, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Machiela MJ, Kim YH, Oh IJ, Lee VHF, Chang GC, Chen KY, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Gao YT, Liu J, Schwartz AG, Houlston R, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold SM, Brennan P, McKay J, Field JK, Davies MPA, Shete SS, Le Marchand L, Liu G, Andrew AS, Kiemeney LA, et al. Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers. J Natl Cancer Inst. 2025 Oct 1:djaf272. doi: 10.1093/jnci/djaf272. Online ahead of print. [pubmed]

 [2024]

*1. Aoyama R, Komatsu M, Harada N, Komatsu R, Sakai A, Takeda K, Teraya N, Asada K, Kaneko S, Iwamoto K, Matsuoka R, Sekizawa A, Hamamoto R. Automated Assessment of the Pulmonary Artery-to-Ascending Aorta Ratio in Fetal Cardiac Ultrasound Screening Using Artificial Intelligence. Bioengineering (Basel). 2024 Dec 12;11(12):1256. [pubmed]

*2. Kouno N, Takahashi S, Takasawa K, Komatsu M, Ishiguro N, Takeda K, Matsuoka A, Fujimori M, Yokoyama K, Yamamoto S, Honma Y, Kato K, Obama K, Hamamoto R. Analysis of Inertial Measurement Unit Data for an AI-Based Physical Function Assessment System Using In-Clinic-like Movements. Bioengineering (Basel). 2024 Dec 5;11(12):1232. [pubmed]

*3. Tanimoto S, Sone K, Toyohara Y, Hachijyo R, Suzuki E, Inoue F, Honjoh H, Fukuda T, Taguchi A, Miyamoto Y, Iriyama T, Uchino-Mori M, Asada K, Komatsu M, Kaneko S, Hamamoto R, Oda K, Hirota Y, Osuga Y. BET inhibitor JQ1 induces apoptosis of ovarian and endometrial endometrioid carcinoma cells by downregulating c-Myc. Oncol Lett. 2024 Dec 19;29(3):106. [pubmed]

*4. Kouno N, Takahashi S, Komatsu M, Sakaguchi Y, Ishiguro N, Takeda K, Fujioka K, Matsuoka A, Fujimori M, Hamamoto R. Introduction of AI Technology for Objective Physical Function Assessment. Bioengineering (Basel). 2024 Nov 16;11(11):1154. [pubmed]

*5. Takahashi S, Sakaguchi Y, Kouno N, Takasawa K, Ishizu K, Akagi Y, Aoyama R, Teraya N, Bolatkan A, Shinkai N, Machino H, Kobayashi K, Asada K, Komatsu M, Kaneko S, Sugiyama M, Hamamoto R. Comparison of Vision Transformers and Convolutional Neural Networks in Medical Image Analysis: A Systematic Review. J Med Syst. 2024 Sep 12;48(1):84. [pubmed]

*6. Kato MK, Fujii E, Asami Y, Momozawa Y, Hiranuma K, Komatsu M, Hamamoto R, Ebata T, Matsumoto K, Ishikawa M, Kohno T, Kato T, Yoshida H, Shiraishi K. Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer.Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16121. Online ahead of print. [pubmed]

*7.  Asada K, Kaneko S, Takasawa K, Shiraishi K, Shinkai N, Shimada Y, Takahashi S, Machino H, Kobayashi K, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Kohno T, Hamamoto R. Multi-omics and clustering analyses reveal the mechanisms underlying unmet needs for patients with lung adenocarcinoma and identify potential therapeutic targets. Mol Cancer. 2024 Sep 2;23(1):182. [pubmed]

*8. Kobayashi K, Takamizawa Y, Miyake M, Ito S, Gu L, Nakatsuka T, Akagi Y, Harada T, Kanemitsu Y, Hamamoto R. Can physician judgment enhance model trustworthiness? A case study on predicting pathological lymph nodes in rectal cancer. Artif Intell Med. 2024 Aug;154:102929. [pubmed]

*9.  Kaneko S, Takasawa K, Asada K, Shiraishi K, Ikawa N, Machino H, Shinkai N, Matsuda M, Masuda M, Adachi S, Takahashi S, Kobayashi K, Kouno N, Bolatkan A, Komatsu M, Yamada M, Miyake M, Watanabe H, Tateishi A, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Saloura V, Kohno T, Hamamoto R. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations. Mol Cancer. 2024 Jun 11;23(1):126. [pubmed]

*10. Fujii E, Kato MK, Yamaguchi M, Higuchi D, Koyama T, Komatsu M, Hamamoto R, Ishikawa M, Kato T, Kohno T, Shiraishi K, Yoshida H. Genomic profiles of Japanese patients with vulvar squamous cell carcinoma. Sci Rep. 2024 Jun 6;14(1):13058. [pubmed]

*11. Takasawa K, Asada K, Kaneko S, Shiraishi K, Machino H, Takahashi S, Shinkai N, Kouno N, Kobayashi K, Komatsu M, Mizuno T, Okubo Y, Mukai M, Yoshida T, Yoshida Y, Horinouchi H, Watanabe SI, Ohe Y, Yatabe Y, Kohno T, Hamamoto R. Advances in cancer DNA methylation analysis with methPLIER: Use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability. Exp Mol Med. 2024 Mar;56(3):646-655. [pubmed]

*12. Mochizuki A, Shiraishi K, Honda T, Higashiyama RI, Sunami K, Matsuda M, Shimada Y, Miyazaki Y, Yoshida Y, Watanabe SI, Yatabe Y, Hamamoto R, Kohno T. Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis. J Thorac Oncol. 2024 Jul;19(7):984-994. [pubmed]

*13. Kobayashi K, Gu L, Hataya R, Mizuno T, Miyake M, Watanabe H, Takahashi M, Takamizawa Y, Yoshida Y, Nakamura S, Kouno N, Bolatkan A, Kurose Y, Harada T, Hamamoto R. Sketch-based semantic retrieval of medical images. Med Image Anal. 2024 Feb;92:103060. [pubmed]

*14. Kato H, Hayami S, Ueno M, Suzaki N, Nakamura M, Yoshimura T, Miyamoto A, Shigekawa Y, Okada K, Miyazawa M, Kitahata Y, Hamamoto R, Ehata S, Yamaue H, Kawai M. Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma. Cancer Sci. 2024 Feb;115(2):385-400. [pubmed]

 
 [2023]

*1. Hayashi T, Takasawa K, Yoshikawa T, Hashimoto T, Sekine S, Wada T, Yamagata Y, Suzuki H, Abe S, Yoshinaga S, Saito Y, Kouno N, Hamamoto R. A discrimination model by machine learning to avoid gastrectomy for early gastric cancer. Ann Gastroenterol Surg. 2023 Jul 13;7(6):913-921. [pubmed]

*2. Shiraishi K, Takahashi A, Momozawa Y, Daigo Y, Kaneko S, Kawaguchi T, Kunitoh H, Matsumoto S, Horinouchi H, Goto A, Honda T, Shimizu K, Torasawa M, Takayanagi D, Saito M, Saito A, Ohe Y, Watanabe SI, Goto K, Tsuboi M, Tsuchihara K, Takata S, Aoi T, Takano A, Kobayashi M, Miyagi Y, Tanaka K, Suzuki H, Maeda D, Yamaura T, Matsuda M, Shimada Y, Mizuno T, Sakamoto H, Yoshida T, Goto Y, Yoshida T, Yamaji T, Sonobe M, Toyooka S, Yoneda K, Masago K, Tanaka F, Hara M, Fuse N, Nishizuka SS, Motoi N, Sawada N, Nishida Y, Kumada K, Takeuchi K, Tanno K, Yatabe Y, Sunami K, Hishida T, Miyazaki Y, Ito H, Amemiya M, Totsuka H, Nakayama H, Yokose T, Ishigaki K, Nagashima T, Ohtaki Y, Imai K, Takasawa K, Minamiya Y, Kobayashi K, Okubo K, Wakai K, Shimizu A, Yamamoto M, Iwasaki M, Matsuda K, Inazawa J, Shiraishi Y, Nishikawa H, Murakami Y, Kubo M, Matsuda F, Kamatani Y, Hamamoto R, Matsuo K, Kohno T. Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses. Cancer Commun (Lond). 2023 Oct 26. doi: 10.1002/cac2.12498. [pubmed]

*3. Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, Shozu K, Asada K, Kaneko S, Yoshida H, Kato T, Nakayama K, Saloura V, Kyo S, Hamamoto R. Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas. Exp Mol Med. 2023 Oct;55(10):2205-2219. [pubmed]

*4. Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02427-3. [pubmed]

*5. Igarashi T, Mazevet M, Yasuhara T, Yano K, Mochizuki A, Nishino M, Yoshida T, Yoshida Y, Takamatsu N, Yoshimi A, Shiraishi K, Horinouchi H, Kohno T, Hamamoto R, Adachi J, Zou L, Shiotani B. An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nat Commun. 2023 Aug 17;14(1):4991. [pumed]

*6. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, Kohno T, Yatabe Y, Kanemitsu Y, Hamamoto R, Takashima A, Shiraishi K, Sekine S. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. Br J Cancer. 2023 Oct;129(7):1176-1183. [pubmed]

*7. Hiranuma K, Asami Y, Kato MK, Murakami N, Shimada Y, Matsuda M, Yazaki S, Fujii E, Sudo K, Kuno I, Komatsu M, Hamamoto R, Makinoshima H, Matsumoto K, Ishikawa M, Kohno T, Terao Y, Itakura A, Yoshida H, Shiraishi K, Kato T. Rare FGFR fusion genes in cervical cancer and transcriptome-based subgrouping of patients with a poor prognosis. Cancer Med. 2023 Sep;12(17):17835-17848. [pubmed]

*8. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Song B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Funderburk KM, Li S, Zhang T, Breeze C, Wang Z, Blechter B, Bassig BA, Kim JH, Albanes D, Wong JYY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Ho JCM, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood DH, Kunitoh H, Patel H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Lee VHF, Chang GC, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, Schwartz AG, Houlston R, Spitz MR, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold S, Brennan P, et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat Commun. 2023 May 26;14(1):3043. doi: 10.1038/s41467-023-38196-z.  [pubmed]

*9. Ohata H, Shiokawa D, Sakai H, Kanda Y, Okimoto Y, Kaneko S, Hamamoto R, Nakagama H, Okamoto K. PROX1 induction by autolysosomal activity stabilizes persister-like state of colon cancer via feedback repression of the NOX1-mTORC1 pathway. Cell Rep. 2023 May 17: 112519. doi: 10.1016/j.celrep.2023.112519. [pubmed]

*10. Kim K, Ryu TY, Jung E, Lee J, Han TS, Kim SK, Roh YN, Lee MS, Jung CR, Lim JH, Hamamoto R, Lee HW, Hur K, Son MY, Kim DS, Cho HS. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis. Exp Mol Med. 2023 May;55(5):952-964. [pubmed]

*11. Shirasawa T, Yoshida T, Shiraishi K, Takigami A, Takayanagi D, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe S, Ohe Y. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy. Lung Cancer. 2023 Mar 25;179:107183. [pubmed]

*12. Hamamoto R, Takasawa K, Shinkai N, Machino H, Kouno N, Asada K, Komatsu M, Kaneko S. Analysis of super-enhancer using machine learning and its application to medical biology. Brief Bioinform. 2023 Mar 23;bbad107. [pubmed]

*13. Ito T, Takayanagi D, Sekine S, Hashimoto T, Shimada Y, Matsuda M, Yamada M, Hamamoto R, Kato T, Shida D, Kanemitsu Y, Boku N, Kohno T, Takashima A, Shiraishi K. Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts. Sci Rep. 2023 Mar 3;13(1):3587. [pubmed]

*14. Asami Y, Kobayashi Kato M, Hiranuma K, Matsuda M, Shimada Y, Ishikawa M, Koyama T, Komatsu M, Hamamoto R, Nagashima M, Terao Y, Itakura A, Kohno T, Sekizawa A, Matsumoto K, Kato T, Shiraishi K, Yoshida H. Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer. Br J Cancer. 2023 Apr;128(8):1582-1591. [pubmed]

 [2022]

*1. Dozen A, Shozu K, Shinkai N, Ikawa N, Aoyama R, Machino H, Asada K, Yoshida H, Kato T, Hamamoto R, Kaneko S, Komatsu M. Tumor Suppressive Role of the PRELP Gene in Ovarian Clear Cell Carcinoma. J Pers Med. 2022 Dec 2;12(12):1999. [pubmed]

*2. Shozu K, Kaneko S, Shinkai N, Dozen A, Kosuge H, Nakakido M, Machino H, Takasawa K, Asada K, Komatsu M, Tsumoto K, Ohnuma SI, Hamamoto R. Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer. Clin Epigenetics. 2022 Nov 12;14(1):147. [pubmed]

*3. Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, Tanimoto S, Taguchi A, Fukuda T, Miyamoto Y, Tanikawa M, Mori-Uchino M, Tsuruga T, Iriyama T, Matsumoto Y, Nagasaka K, Wada-Hiraike O, Oda K, Hamamoto R, Osuga Y. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells. Cancers (Basel). 2022 Oct 31;14(21):5367. [pubmed]

*4. Hossain E, Abdelrahim M, Tanasescu A, Yamada M, Kondo H, Yamada S, Hamamoto R, Marugame A, Saito Y, Bhandari P. Performance of a novel computer-aided diagnosis system in the characterization of colorectal polyps, and its role in meeting Preservation and Incorporation of Valuable Endoscopic Innovations standards set by the American Society of Gastrointestinal Endoscopy. DEN Open. 2022 Oct 28;3(1):e178. [pubmed]

*5. Hamamoto R, Koyama T, Kouno N, Yasuda T, Yui S, Sudo K, Hirata M, Sunami K, Kubo T, Takasawa K, Takahashi S, Machino H, Kobayashi K, Asada K, Komatsu M, Kaneko S, Yatabe Y, Yamamoto N. Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Exp Hematol Oncol. 2022 Oct 31;11(1):82. [pubmed]

*6. Hopkins J, Asada K, Leung A, Papadaki V, Davaapil H, Morrison M, Orita T, Sekido R, Kosuge H, Reddy MA, Kimura K, Mitani A, Tsumoto K, Hamamoto R, Sagoo MS, Ohnuma SI. PRELP Regulates Cell-Cell Adhesion and EMT and Inhibits Retinoblastoma Progression. Cancers (Basel). 2022 Oct 8;14(19):4926. [pubmed]

*7. Yamada M, Shino R, Kondo H, Yamada S, Takamaru H, Sakamoto T, Bhandari P, Imaoka H, Kuchiba A, Shibata T, Saito Y, Hamamoto R. Robust automated prediction of the revised Vienna Classification in colonoscopy using deep learning: development and initial external validation. J Gastroenterol. 2022 Nov;57(11):879-889. [pubmed]

*8. Hamamoto R, Takasawa K, Machino H, Kobayashi K, Takahashi S, Bolatkan A, Shinkai N, Sakai A, Aoyama R, Yamada M, Asada K, Komatsu M, Okamoto K, Kameoka H, Kaneko S. Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine. Brief Bioinform. 2022 Jul 18;23(4):bbac246. doi: 10.1093/bib/bbac246. [pubmed]

*9. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S. Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer. Br J Cancer. 2022 Oct;127(6):1043-1050. [pubmed]

*10. Ono S, Komatsu M, Sakai A, Arima H, Ochida M, Aoyama R, Yasutomi S, Asada K, Kaneko S, Sasano T, Hamamoto R. Automated Endocardial Border Detection and Left Ventricular Functional Assessment in Echocardiography Using Deep Learning. Biomedicines. 2022 May 6;10(5):1082. [pubmed]

*11. Tanosaki T, Mikami Y, Shindou H, Suzuki T, Hashidate-Yoshida T, Hosoki K, Kagawa S, Miyata J, Kabata H, Masaki K, Hamamoto R, Kage H, Miyashita N, Makita K, Matsuzaki H, Suzuki Y, Mitani A, Nagase T, Shimizu T, Fukunaga K. Lysophosphatidylcholine Acyltransferase 1 Deficiency Promotes Pulmonary Emphysema via Apoptosis of Alveolar Epithelial Cells. Inflammation. 2022 Mar 26. [pubmed]

*12. Sakai A, Komatsu M, Komatsu R, Matsuoka R, Yasutomi S, Dozen A, Shozu K, Arakaki T, Machino H, Asada K, Kaneko S, Sekizawa A, Hamamoto R. Medical Professional Enhancement Using Explainable Artificial Intelligence in Fetal Cardiac Ultrasound Screening. Biomedicines. 2022 Feb 25;10(3):551. [pubmed]

*13. Kobayashi Kato M, Asami Y, Takayanagi D, Matsuda M, Shimada Y, Hiranuma K, Kuno I, Komatsu M, Hamamoto R, Matsumoto K, Ishikawa M, Kohno T, Kato T, Shiraishi K, Yoshida H. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma. Cancer Sci. 2022 May;113(5):1712-1721. [pubmed]

*14. Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R. The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. Commun Biol. 2022 Jan 11;5(1):39. [pubmed]

*15. Bolatkan A, Asada K, Kaneko S, Suvarna K, Ikawa N, Machino H, Komatsu M, Shiina S, Hamamoto R. Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. Int J Oncol. 2022 Jan;60(1):4. [pubmed]

*16. Ryu TY, Kim K, Han TS, Lee MO, Lee J, Choi J, Jung KB, Jeong EJ, An DM, Jung CR, Lim JH, Jung J, Park K, Lee MS, Kim MY, Oh SJ, Hur K, Hamamoto R, Park DS, Kim DS, Son MY, Cho HS. Human gut-microbiome derived propionate coordinates proteasomal degradation via HECTD2 upregulation to target EHMT2 in colorectal cancer. The ISME Journal. 2022 May;16(5):1205-1221 [pubmed]

 [2021]

*1. Hamamoto R: Application of Artificial Intelligence for Medical Research. Biomolecules, 11, 90 (2021) [pubmed]

*2. Komatsu M, Sakai A, Komatsu R, Matsuoka R, Yasutomi S, Shozu K, Dozen A, Machino H, Hidaka H, Arakaki T, Asada K, Kaneko S, Sekizawa A, Hamamoto R: Cardiac Structural Abnormalities in Fetal Ultrasound Videos Using Deep Learning. Applied Sciences, 11, 371 (2021) [link]

*3. Yasutomi S, Arakaki T, Matsuoka R, Sakai A, Komatsu R, Shozu K, Dozen A, Machino H, Asada K, Kaneko S, Dozen A, Machino H, Asada K, Kaneko S, Sekizawa A, Hamamoto R, Komatsu M: Shadow Estimation for Ultrasound Images Using Auto-Encoding Structures and Synthetic Shadows. Applied Sciences, 11, 1127 (2021) [link]

*4. Kobayashi K, Hamamoto R, Itami J: Tensor regression-based model to investigate heterogeneous spatial radiosensitivity after I-125 seed implantation for prostate cancer. In Vivo, 35, 489-497 (2021) [pubmed]

*5. Ozawa T, Kaneko S, Szulzewsky F, Qiao Z, Takadera M, Narita Y, Kondo T, Holland EC, Hamamot R, Ichimura K: C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta Neuropathologica Communications, 9, 36 (2021) [pubmed]

*6. Takayanagi D, Hirose S, Kuno I, Asami Y, Murakami N, Matsuda M, Shimada Y, Sunami K, Komatsu M, Hamamoto R, Kobayashi-Kato M, Matsumoto K, Kohno T, Kato T, Shiraishi K, Yoshida H: Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. Cancers (Basel), 13, 1215 (2021) [pubmed]

*7. Takahashi S, Takahashi M, Kinoshita M, Miyake M, Kawaguchi R, Shinojima N, Mukasa A, Saito K, Nagane M, Otani R, Higuchi F, Tanaka S, Hata N, Tamura K, Tateishi K, Nishikawa R, Arita H, Nonaka M, Uda T, Fukai J, Okita Y, Tsuyuguchi N, Kanemura Y, Kobayashi K, Sese J, Ichimura k, Narita Y, Hamamoto R: Fine-Tuning Approach for Segmentation of Gliomas in Brain Magnetic Resonance Images with a Machine Learning Method to Normalize Image Differences among Facilities. Cancers (Basel), 13, 1415 (2021) [pubmed]

*8. Takahashi S, Takahashi M, Tanaka S, Takayanagi S, Takami H, Yamazawa E, Nambu S, Miyake M, Satomi K, Ichimura K, Narita Y, Hamamoto R: A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning. Biomolecules, 11, 565 (2021) [pubmed]

*9. Kaneko S, Mitsuyama T, Shiraishi K, Ikawa N, Shozu K, Dozen A, Machino H, Asada K, Komatsu M, Kukita A, Sone K, Yoshida H, Motoi N, Hayami S, Yoneoka Y, Kato T, Kohno T, Natsume T, Keudell GV, Saloura V, Yamaue H, Hamamoto R: Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential. Cancers (Basel), 13, 2126 (2021) [pubmed]

*10. Asada K, Kaneko S, Takasawa K, Machino H, Takahashi S, Shinkai N, Shimoyama R, Komatstu M, Hamamoto R: Integrated Analysis of Whole Genome and Epigenome Data Using Machine Learning Technology: Toward the Establishment of Precision Oncology. Front Oncol,13, 666397 (2021) [pubmed]

*11. Kobayashi K, Miyake M, Takahashi M, Hamamoto R: Observing Deep Radiomics for the Classification of Glioma Grades. Sci Rep,11, 10942 (2021) [pubmed]

*12. Komatsu M, Sakai A, Dozen A, Shozu A, Yasutomi S, Machino H, Asada K, Kaneko S, Hamamoto R: Towards Clinical Application of Artificial Intelligence in Ultrasound Imaging. Biomedicines,9, 720 (2021) [pubmed]

*13. Yamada M, Saito Y, Yamada S, Kondo H, Hamamoto R: Detection of flat colorectal neoplasia by artificial intelligence: A systematic review. Best Pract Res Clin Gastroenterol, 52-53, 101745 (2021) [pubmed]

*14. Kawaguchi RK, Takahashi M, Miyake M, Kinoshita M, Takahashi S, Ichimura K, Hamamoto R, Narita Y, Sese J: Assessing Versatile Machine Learning Models for Glioma Radiogenomic Studies across Hospitals. Cancers (Basel), 13, 3611 (2021) [pubmed]

*15. Kobayashi K, Hataya R, Kurose Y, Miyake M, Takahashi M, Nakagawa A, Harada T, Hamamoto R: Decomposing normal and abnormal features of medical images for content-based image retrieval of glioma imaging. Med Image Anal, 8;74:102227 (2021) [pubmed]

*16. Kaneko S, Takasawa K, Asada K, Shinkai N, Bolatkan A, Yamada M, Takahashi S, Machino H, Kobayashi K, Komatsu M, Hamamoto R: Epigenetic Mechanisms Underlying COVID-19 Pathogenesis. Biomedicines, 9, 1142 (2021) [pubmed]

*17. Asada K, Komatsu M, Shimoyama R, Takasawa K, Shinkai N, Sakai A, Bolatkan A, Yamada M, Takahashi S, Machino H, Kobayashi K, Kaneko S, Hamamoto R: Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. J Pers Med, 11, 886 (2021) [pubmed]

*18. Kuno I, Takayanagi D, Asami Y, Murakami N, Matsuda M, Shimada Y, Hirose S, Kato MK, Komatsu M, Hamamoto R, Okuma K, Kohno T, Itami J, Yoshida H, Shiraishi K, Kato T: TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Sci Rep, 11, 19261 (2021) [pubmed]

*19. Asada K, Takasawa K, Machino H, Takahashi S, Shinkai N, Bolatkan A, Kobayashi K, Komatsu M, Kaneko S, Okamoto K, Hamamoto R: Single-Cell Analysis Using Machine Learning Techniques and Its Application to Medical Research. Biomedicines, 9, 1513 (2021) [pubmed]

*20. Lee K, Kim K, Ryu TY, Jung CR, Lee MS, Lim JH, Park K, Kim DS, Son MY, Hamamoto R, Cho HS: EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression. Mol Oncol, 15, 2989-3002 (2021) [pubmed]

 [2020]

*1. Hirose S, Murakami N, Takahashi K, Kuno I, Takayanagi D, Asami Y, Matsuda M, Shimada Y, Yamano S, Sunami K, Yoshida K, Honda T, Nakahara T, Watanabe T, Komatsu M, Hamamoto R, Kobayashi-Kato M, Matsumoto K, Okuma K, Kuroda T, Okamoto A, Itami J, Kohno T, Kato T, Shiraishi K, Yoshida H: Genomic Alterations in STK11 Can Predict Clinical Outcomes in Cervical Cancer Patients. Gynecol Oncol, 156, 203-210 (2020) [pubmed]

*2. Isago H, Mitani A, Mikami Y, Horie M, Urushiyama H, Hamamoto R, Terasaki Y, Nagase T: Replcation stress triggers microsatellite destabilization and hypermutation leading to clonal expansion in vitro. American Journal of Respiratory Cell and Molecular Biology, 62, 256-266 (2020) [pubmed]

*3. Hamamoto R, Komatsu M, Takasawa K, Asada K, Kaneko S: Epigenetics Analysis and Integrated Analysis of Multiomics Data, Including Epigenetic Data, Using Artificial Intelligence in the Era of Precision Medicine. Biomolecules, 10, 62 (2020) [pubmed]

*4. Asada K, Kobayashi K, Joutard S, Tubaki M, Takahashi S, Takasawa K, Komatsu M, Kaneko S, Sese J, Hamamoto R: Uncovering Prognosis-related Genes and Pathways by Multi-omics Analysis in Lung Cancer. Biomolecules, 10, 524 (2020) [pubmed]

*5. Saloura V, Vougiouklakis T, Bao R, Kim S, Baek S, Zewde M, Bernard B, Burkitt K, Nigam N, Izumchenko E, Dohmae N, Hamamoto R, Nakamura Y: WHSC1 monomethylates histone H1 and induces stem-cell like features in squamous cell carcinoma of the head and neck. Neoplasia, 22, 283-293 (2020) [pubmed]

*6. Asada K, Bolatkan A, Takasawa K, Komatsu M, Kaneko S, Hamamoto R: Critical Roles of N⁶-Methyladenosine (m⁶A) in Cancer and Virus Infection. Biomolecules, 10, 1071 (2020) [pubmed]

*7. Jinnai S, Yamazaki N, Hirano Y, Sugawara Y, Ohe Y, Hamamoto R: The Development of a Skin Cancer Classification System for Pigmented Skin Lesions Using Deep Learning. Biomolecules, 10, 1123 (2020) [pubmed]

*8. Kobayashi K, Bolatkan A, Shiina S, Hamamoto R: Fully-Connected Neural Networks with Reduced Parameterization for Predicting Histological Types of Lung Cancer from Somatic Mutations. Biomolecules, 10, 1249 (2020) [pubmed]

*9. Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Kawata A, Honjoh H, Kawata Y, Kashiyama T, Sato M, Taguchi A, Miyamoto Y, Tanikawa M, Tsuruga T, Nagasaka K, Wada-Hiraike O, Osuga Y, Fujii T: The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells. Oncology Letters, 20, 153 (2020) [pubmed]

*10. Kageyama SI, Du J, Kaneko S, Hamamoto R, Yamaguchi S, Yamashita R, Okumura M, Motegi A, Hojo H, Nakamura M, Tsuchihara K, Akimoto T: Identification of the mutation signature of the cancer genome caused by irradiation. Radiotherapy and Oncology, 20, 155 (2020) [pubmed]

*11. Takahashi S, Asada K, Takasawa K, Shimoyama R, Sakai A, Bolatkan A, Shinkai N, Kobayashi K, Komatsu M, Kaneko S, Sese J, Hamamoto R: Predicting Deep Learning Based Multi-Omics Parallel Integration Survival Subtypes in Lung Cancer Using Reverse Phase Protein Array Data. Biomolecules, 10, 1460 (2020) [pubmed]

*12. Dozen A, Komatsu M, Sakai A, Komatsu R, Shozu K, Machino H, Yasutomi S, Arakaki T, Asada K, Kaneko S, Matsuoka R, Aoki D, Sekizawa A, Hamamoto R: Image Segmentation of the Ventricular Septum in Fetal Cardiac Ultrasound Videos Based on Deep Learning Using Time-Series Information. Biomolecules, 10, 1526 (2020) [pubmed]

*13. Papadaki V, Asada K, Watson JK, Tamura T, Leung A, Hopkins J, Dellett M, Sasai N, Davaapil H, Nik-Zainal S, Longbottom R, Nakakido M, Torii R, Veerakumarasivam A, Kaneko S, Sagoo MS, Murphy G, Mitani A, Tsumoto K, Kelly JD, Hamamoto R, Ohnuma SI: Two Secreted Proteoglycans, Activators of Urothelial Cell-Cell Adhesion, Negatively Contribute to Bladder Cancer Initiation and Progression. Cancers (Basel), 12, 3362 (2020) [pubmed]

*14. Hamamoto R, Suvarna K, Yamada M, Kobayashi K, Shinkai N, Miyake M, Takahashi M, Jinnai S, Shimoyama R, Sakai A, Takasawa K, Bolatkan A, Shozu K, Dozen A, Machino H, Takahashi S, Asada K, Komatsu M, Sese J, Kaneko S: Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine. Cancers (Basel), 12, 3532 (2020) [pubmed]

*15. Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T: Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer. Biomolecules, 10, 1686 (2020) [pubmed]

*16. Shozu K, Komatsu M, Sakai A, Komatsu R, Dozen A, Machino H, Yasutomi S, Arakaki T, Asada K, Kaneko S, Matsuoka R, Nakashima A, Sekizawa A, Hamamoto R: Model-Agnostic Method for Thoracic Wall Segmentation in Fetal Ultrasound Videos. Biomolecules, 10, 1691 (2020) [pubmed]

 
 [2019]

*1. Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y: A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinoma. The Annals of Thoracic Surgery, 9, 34320-34335 (2019) [pubmed]

*2. Kim SK, Kim K, Ryu JW, Ryu TY, Lim JH, Oh JH, Min JK, Jung CR, Hamamoto R, Son MY, Kim DS, Cho HS: The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer. International Journal of Oncology, 54, 65-76 (2019) [pubmed]

*3. Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Hiraike O, Osuga Y, Fujii T: Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas. Biochemical and Biophysical Research Communications, 513, 340-346 (2019) [pubmed]

*4. Kojima M, Sone K, Oda K, Hamamoto R, Kaneko S, Oki S, Kukita A, Machino H, Honjoh H, Kawata Y, Kashiyama T, Asada K, Tanikawa M, Mori-Uchino M, Tsuruga T, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T: The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation. BMC Cancer, 19, 455 (2019) [pubmed]

*5. Kobayashi K, Murakami N, Takahashi K, Inaba K, Hamamoto R, Itami J: Local Radiotherapy or Chemotherapy for Oligo-recurrent Cervical Cancer in Patients With Prior Pelvic Irradiation. In Vivo, 33, 1659-1665 (2019) [pubmed]

*6. Matsuno Y, Atsumi Y, Shimizu A, Katayama K, Fujimori H, Hyodo M, Minakawa Y, Nakatsu Y, Kaneko S, Hamamoto R, Shimamura T, Miyano S, Tsuzuki T, Hanaoka F, Yoshioka KI: Replication stress triggers microsatellite destabilization and hypermutation leading to clonal expansion in vitro. Nature Communications, 10, 3925 (2019) [pubmed]

*7. Yamada M, Saito Y, Imaoka H, Saiko M, Yamada S, Kondo H, Takamaru H, Sakamoto T, Sese J, Kuchiba A, Shibata T, Hamamoto R: Developmentof a real-time endoscopic image diagnosis support system using deep learning technology in colonoscopy. Scientific Reports, 9, 14465 (2019) [pubmed]

*8. Kobayashi K, Murakami N, Takahashi K, Inaba K, Igaki H, Hamamoto R, Itami J:A Population-based Statistical Model for Investigating Heterogeneous intraprostatic Sensitivity to Radiation Toxicity After ¹²⁵I Seed Implantation. In Vivo, 33, 2103-2111 (2019) [pubmed]

*9. Kim S, Bolatkan A, Kaneko S, Ikawa N, Asada K, Komatsu M, Hayami S, Ojima H, Abe N, Yamaue H, Hamamoto R: Deregulation of the histone lysine specific demethylase 1 is involved in human hepatocellular carcinoma. Biomolecules, 9, 810 (2019) [pubmed]

 [2018]

*1. Piao L, Fujioka K, Nakakido M, Hamamoto R: Regulation of poly(ADP-Ribose) polymerase 1 functions by post-translational modifications. Frontiers in Bioscience, 23, 13-26 (2018) [pubmed]

*2. Kunizaki M, Tominaga T, Wakata K, Miyazaki T, Matsumoto K, Sumida Y, Hidaka S, Yamasaki T, Yasutake T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T: Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. Molecular and Clinical Oncology, 8, 370-374 (2018) [pubmed]

*3. Kunizaki M, Hamasaki K, Wakata K, Tobinaga S, Sumida Y, Hidaka S, Yasutake T, Miyazaki T, Matsumoto K, Yamasaki T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T: Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous. Anticancer Research, 38, 1807-1813 (2018) [pubmed]

*4. Toyokawa G, Takada K, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Yamada Y, Hamamoto R, Oda Y, Maehara Y: Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer. Anticancer Research, 38, 3707-3711 (2018) [pubmed]

*5. Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R, Yamaue H:　Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget, 9, 34320-34335 (2018) [pubmed]

*6. Lee CH, Yu JR, Kumar S, Jin Y, LeRoy G, Bhanu N, Kaneko S, Garcia BA, Hamilton AD, Reinberg D: Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin. Molecular Cell, 70, 422-434 (2018) [pubmed]

 
 [2017]

*1. Saloura V, Vougiouklakis T, Zewde M, Suzuki T, Dohmae N, Deng X, Kiyotani K, Park J-H, Matsuo Y, Lingen M, Hamamoto R, Nakamura Y: WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR. Scientific Reports, 7, 40664 (2017) [pubmed]

*2. Toyokawa G, Takada K, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Hamamoto R, Oda Y, Maehara Y: Elevated metabolic activity on ¹⁸F-FDG PET/CT defines EZH2-expressing non-small cell lung cancer. Anticancer Research, 37, 1393-1401 (2017) [pubmed]

*3. Oki S, Sone K, Oda K, Hamamoto R, Ikemura M, Maeda D, Takeuchi M, Tanikawa M, Mori-Uchino M, Nagasaka K, Miyasaka A, Kashiyama T, Ikeda Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Fukayama M, Osuga Y, Fujii T: Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. Oncotarget, 8, 40402-40411 (2017) [pubmed]

*4．Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL: Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention. Cancer Prevention Research, 10, 255-266 (2017) [pubmed]

*5．Wang R, Deng X, Yoshioka Y, Vougiouklakis T, Park JH, Suzuki T, Dohmae N, Ueda K, Hamamoto R, Nakamura Y: Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells. Cancer Science, 18:1203-1209 (2017) [pubmed]

*6.  Kunizaki M, Fukuda A, Wakata K, Tominaga T, Nonaka T, Miyazaki T, Matsumoto K, Sumida Y, Hidaka S, Yasutake T, Sawai T, Hamamoto R, Nanashima A, Nagayasu T. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer. Anticancer Research, 37, 1979-1984 (2017) [pubmed]

*7．Deng X, Hamamoto R, Vougiouklakis T, Wang R, Yoshioka Y, Suzuki T, Dohmae N, Matsuo Y, Park JH, Nakamura Y. Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget, 8, 55837-55847 (2017) [pubmed]

*8．*Yoshioka Y, Suzuki T, Matsuo Y, Tsurita G, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization. Cancer Medicine, 6, 1665-1672 (2017) [pubmed]

 
 [2016]

*1. Hamamoto R, Nakamura Y: Dysregulation of protein methyltransferases in human cancer: an emerging target class for anticancer therapy. Cancer Science, 107, 377-384 (2016)

*2. Piao L, Nakakido M, Suzuki T, Dohmae N, Nakamura Y, Hamamoto R: Automethylation of SUV39H2, an oncogenic histone lysine methyltransferase, regulates its binding affinity to substrate proteins. Oncotarget, 7, 22846-22856 (2016)

*3. Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park J-H, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R: WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget, 7, 42527-42538 (2016)

*4. Kunizaki M, Sawai T, Takeshita H, Tominaga T, Hidaka S, To K, Miyazaki T, Hamamoto R, Nanashima A, Nagayasu T: Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer. Anticancer Research, 36, 4171-4175 (2016)

*5. Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Park J-H, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y: The prognostic impact of jumonji domain containing 2B in patients with resected lung adenocarcinoma. Anticancer Research, 36, 4841-4846 (2016)

*6. Yoshioka Y, Suzuki T, Matsuo Y, Nakakido M, Tsurita G, Simone C, Watanabe T, Dohmae N, Nakamura Y, Hamamoto R†: SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget, 7, 75023-75037 (2016)

*7. Deng Y, Wang H, Hamamoto R, Duan S, Pirooznia M, Bai Y: Functional Genomics, Genetics, and Bioinformatics 2016. BioMed Research International, Article ID 2625831 (2016)

 [2015]

*1. Theodore Vougiouklakis, Kenbun Sone, Vassiliki Saloura, Hyun-Soo Cho, Takehiro Suzuki, Naoshi Dohmae, Houda Alachkar, Yusuke Nakamura, Ryuji Hamamoto: SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. Oncotarget, 6 , 43162-43171 (2015)

*2. Xiaolan Deng, Gottfried Von Keudell, Takehiro Suzuki, Naoshi Dohmae, Makoto Nakakido, Lianhua Piao, Yuichiro Yoshioka, Yusuke Nakamura, Ryuji Hamamoto: PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget, 6, 35173-35182 (2015)

*3. Wayne O. Miles, Julie M. J. Lepesant, Jessie Bourdeaux, Manuela Texier, Marc A. Kerenyi, Makoto Nakakido, Ryuji Hamamoto, Stuart H. Orkin, Nicholas J. Dyson, Luisa Di Stefano: The LSD1 family of histone demethylases and the PUMILIO post-transcriptional repressor function in a complex regulatory feedback loop. Molecular and Cellular Biology, 35, 4199-4211 (2015)

*4. Makoto Nakakido, Zhenzhong Deng, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura, Ryuji Hamamoto : PRMT6 increases cytoplasmic localization of p21^CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. Oncotarget, 6, 30957-30967 (2015)

*5. Martin Mutonga, Kenji Tamura, Gregory Malnassy, Noreen Fulton, Amanda de Albuquerque, Ryuji Hamamoto, Wendy Stock, Yusuke Nakamura, Houda Alachkar: Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL). Translational Oncology, 8, 368-375 (2015)

*6. Lianhua Piao, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura, Ryuji Hamamoto: SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget, 6, 16939-16950 (2015)

*7. Youping Deng, Hongwei Wang, Ryuji Hamamoto, David Schaffer, Shiwei Duan: Functional Genomics, Genetics, and Bioinformatics. BioMed Research International, Article ID 184824 (2015)

*8. Theodore Vougiouklakis, Ryuji Hamamoto, Yusuke Nakamura, Vassiliki Saloura: The NSD family of protein methyltransferases in human cancer. Epigenomics, 7, 863-874 (2015)

*9. Makoto Nakakido, Zhenzhong Deng, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura, Ryuji Hamamoto: Dysregulation of AKT Pathway by SMYD2-mediated Lysine Methylation on PTEN. Neoplasia, 17, 367-373 (2015)

*10. Ryuji Hamamoto, Vassiliki Saloura, Yusuke Nakamura: Critical roles of non-histone protein lysine methylation in human tumorigenesis. Nature Reviews Cancer, 15, 110-124 (2015)

*11. Vassiliki Saloura, Hyun-Soo Cho, Kazuma Kyiotani, Houda Alachkar, Zhixiang Zuo, Makoto Nakakido, Tatsuhiko Tsunoda, Tanguy Seiwert, Mark Lingen, Jonathan Licht, Yusuke Nakamura, Ryuji Hamamoto†: WHSC1 Promotes Oncogenesis through Regulation of NIMA-related-kinase-7 in Squamous Cell Carcinoma of the Head and Neck. Molecular Cancer Research, 13, 293-304 (2015)

 
 [2014]

*1. Kenbun Sone, Lianhua Piao, Makoto Nakakido, Koji Ueda, Thomas Jenuwein, Yusuke Nakamura, Ryuji Hamamoto: Critical role of lysine 134 methylation on histone H2AX for g-H2AX production and DNA repair. Nature Communications, 5, 5691 (2014)

*2. Zhenzhong Deng, Koichi Matsuda, Chizu Tanikawa, Jiaying Lin, Yoichi Furukawa, Ryuji Hamamoto, Yusuke Nakamura: Late Cornified Envelope Group I, a Novel Target of p53, Regulates PRMT5 Activity. Neoplasia, 16, 656-664 (2014)

*3. Ryuji Hamamoto, Gouji Toyokawa, Makoto Nakakido, Koji Ueda, Yusuke Nakamura: SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation. Cancer Letters, 351, 126-133 (2014)

*4. Lianhua Piao, Daechun Kang, Takehiro Suzuki, Akiko Masuda, Naoshi Dohmae, Yusuke Nakamura, Ryuji Hamamoto: The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells. Neoplasia, 16, 257-264 (2014)

*5. Syuzo Kaneko, Roberto Bonasio, Ricardo Saldaña-Meyer, Takahaki Yoshida, Jinsook Son, Koichiro Nishino, Akihiro Umezawa, Danny Reinberg: Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Molecular Cell, 53, 290-300 (2014)

*6. Syuzo Kaneko, Jinsook Son, Roberto Bonasio, Steven S. Shen, Danny Reinberg: Nascent RNA interaction keeps PRC2 activity poised and in check. Genes & Development, 28 (18), 1983-1988 (2014)

*7. Simão Teixeira da Rocha, Valentina Boeva, Martin Escamilla-Del-Arenal, Katia Ancelin, Camille Granier, Neuza Reis Matias, Serena Sanulli, Jen Chow, Edda Schulz, Christel Picard, Syuzo Kaneko, Kristian Helin, Danny Reinberg, A. Francis Stewart, Anton Wutz, Raphaël Margueron, Edith Heard. Molecular Cell, 53, 301-316 (2014)

 
 [2013]

*1. Masaharu Kogure, Masashi Takawa, Vassiliki Saloura, Kenbun Sone, Lianhua Piao, Koji Ueda, Reem Ibrahim, Tatsuhiko Tsunoda, Masanori Sugiyama, Yutaka Atomi, Yusuke Nakamura, Ryuji Hamamoto: The Oncogenic Polycomb Histone Methyltransferase EZH2 Methylates Lysine 120 on Histone H2B and Competes Ubiquitination. Neoplasia, 15, 476-486 (2013)

*2. Masaharu Kogure, Masashi Takawa, Hyun-Soo Cho, Gouji Toyokawa, Kazuyuki Hayashi, Tatsuhiko Tsunoda, Takaaki Kobayashi, Yataro Daigo, Masanori Sugiyama, Yutaka Atomi, Yusuke Nakamura, Ryuji Hamamoto: Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G₁/S transition. Cancer Letters, 336, 76-84 (2013)

*3. Motoko Unoki, Akiko Masuda, Naoshi Dohmae, Yoshinori Fukui, Kyohei Arita, Masanori Yoshimatsu, Yukiko Iwai, Koji Ueda, Ryuji Hamamoto, Masahiro Shirakawa, Hiroyuki Sasaki, Yusuke Nakamura: Lysyl 5-Hydroxylation, a Novel Histone Modification, by Jumonji Domain Containing 6. Journalof Biological Chemistry,288, 6053-6062 (2013)

*4. Daechun Kang, Hyun-Soo Cho, Gouji Toyokawa, Masaharu Kogure, Yuka Yamane, Yukiko Iwai, Shinya Hayami, Tatsuhiko Tsunoda, Helen I. Field, Koichi Matsuda, David E. Neal, Bruce A.J. Ponder, Yoshihiko Maehara, Yusuke Nakamura, Ryuji Hamamoto: The Histone Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1-like 1 (WHSC1L1) Is Involved in Human Carcinogenesis. Genes, Chromosomes and Cancer, 52, 126-139 (2013)

*5. Syuzo Kaneko, Jinsook Son, Steven S Shen, Danny Reinberg, Roberto Bonasio: PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells. Nature Structural & Molecular Biology, 20, 1258-1264 (2013)

 
 [2012]

*1. Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, Tsuchiya E, Ohnuma S, Ponder BA, Yoshida M, Nakamura Y, Hamamoto R: Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. Nature Communications, 3, 1072 (2012)

*2. Arita K, Isogai S, Oda T, Unoki M, Sugita K, Sekiyama N, Kuwata K, Hamamoto R, Tochio H, Sato M, Ariyoshi M, Shirakawa M: Recognition of modification status on a histone H3 tail by linked histone reader modules of the epigenetic regulator UHRF1. Proceedings of the National Academy of Sciences of the United States of America, 109, 12950-12955 (2012)

*3. Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, Dohmae N, Kogure M, Kang D, Neal DE, Ponder BA, Yamaue H, Nakamura Y, Hamamoto R: RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia, 14, 476-486 (2012)

*4. Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, Iwai Y, Maejima K, Ueda K, Masuda A, Dohmae N, Field HI, Tsunoda T, Kobayashi T, Akasu T, Sugiyama M, Ohnuma S, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R: Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.  Cancer Research, 72, 3217-3227 (2012)

*5. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, Kelly JD, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R: The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. International Journal of Cancer, 131, E179-189 (2012)

 [2011]

*1. Gouji Toyokawa, Hyun-Soo Cho, Yukiko Iwai, Masanori Yoshimatsu, Masashi Takawa, Shinya Hayami, Kazuhiro Maejima, Noriaki Shimizu, Hirotoshi Tanaka, Tatsuhiko Tsunoda, Helen I. Field, John D. Kelly, David E. Neal, Bruce A.J. Ponder, Yoshihiko Maehara, Yusuke Nakamura, Ryuji Hamamoto: The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prevention Research, 4, 2051-2061 (2011)

*2. Gouji Toyokawa, Hyun-Soo Cho, Ken Masuda, Yuka Yamane, Masanori Yoshimatsu, Shinya Hayami, Masashi Takawa, Yukiko Iwai, Yataro Daigo, Eiju Tsuchiya, Tatsuhiko Tsunoda, Helen I. Field, John D. Kelly, David E. Neal, Yoshihiko Maehara, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: The Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway. Neoplasia, 13, 887-898 (2011)

*3. Hyun-Soo Cho, John D. Kelly, Shinya Hayami, Gouji Toyokawa, Masahi Takawa, Masanori Yoshimatsu, Tatsuhiko Tsunoda, Helen I. Field, David E. Neal, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1. Neoplasia, 13, 676-684 (2011)

*4. Gouji Toyokawa, Ken Masuda, Yataro Daigo, Hyun-Soo Cho, Masanori Yoshimatsu, Masashi Takawa, Shinya Hayami, Kazuhiro Maejima, Makoto Chino, Helen I. Field, David E. Neal, Eijyu Tsuchiya, Bruce A.J. Ponder, Yoshihiko Maehara, Yusuke Nakamura, Ryuji Hamamoto: Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Molecular Cancer, 10, 65 (2011)

*5. Masashi Takawa, Ken Masuda, Masaki Kunizaki, Yataro Daigo, Katsunori Takagi, Yukiko Iwai, Hyun-Soo Cho, Gouji Toyokawa, Yuka Yamane, Kazuhiro Maejima, Helen I. Field, Takaaki Kobayashi, Takayuki Akasu, Masanori Sugiyama, Eijyu Tsuchiya, Yutaka Atomi, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Science, 102, 1298-1305 (2011)

*6. Hyun-Soo Cho, Takehiro Suzuki, Naoshi Dohmae, Shinya Hayami, Motoko Unoki, Masanori Yoshimatsu, Gouji Toyokawa, Masashi Takawa, Taiping Chen, Julia K. Kurash, Helen I. Field, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: Demethylation of MYPT1 by LSD1 promotes cell cycle progression in cancer cells. Cancer Research, 71, 1-6 (2011)

*7. Masanori Yoshimatsu, Gouji Toyokawa, Shinya Hayami, Motoko Unoki, Tatsuhiko Tsunoda, Helen I. Field, John D. Kelly, David E. Neal, Yoshihiko Maehara, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: Dysregulation of PRMT1 and PRMT6, type I arginine methyltransferases, is involved in various types of human cancers. International Journal of Cancer, 128, 562-573 (2011)

*8. Shinya Hayami, John D. Kelly, Hyun-Soo Cho, Masanori Yoshimatsu, Motoko Unoki, Tatsuhiko Tsunoda, Helen I. Field, David E. Neal, Hiroki Yamaue, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto: Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer, 128, 574-586 (2011)